Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Byers
David Byers, Halifax CA
| Patent application number | Description | Published |
|---|---|---|
| 20100076028 | Design and Synthesis of Novel Antimicrobials - The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups. | 03-25-2010 |
David M. Byers, Halifax CA
| Patent application number | Description | Published |
|---|---|---|
| 20100137388 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof - The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R | 06-03-2010 |
Helen Byers, Surrey GB
| Patent application number | Description | Published |
|---|---|---|
| 20090275495 | METHODS AND COMPOSITIONS RELATING TO ALZHEIMER'S DISEASE - Methods and compositions relating to Alzheimer's disease are provided, including proteins that are differentially expressed in Alzheimer's disease as compared to the normal state. Further provided are methods, particularly experimental paradigms, for the identification of differential expressed proteins that are potential molecular targets for compounds to treat or prevent Alzheimer's disease. Also provided are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease. | 11-05-2009 |
| 20110111513 | MASS SPECTROMETRIC ANALYSIS - The disclosure provides a method for assaying for a target analyte, comprising providing a plurality of samples which may comprise the target analyte, wherein each sample is differentially labelled with a mass label or a combination of mass labels, wherein the mass labels are from a set of mass labels, wherein each mass label is an isobaric mass label comprising a mass spectrometrically distinct mass marker group, such that the samples can be distinguished by mass spectrometry and determining from the mass spectrum the quantity of the target analyte in each sample. | 05-12-2011 |
Helen Byers, Cobham Surrey GB
| Patent application number | Description | Published |
|---|---|---|
| 20110165146 | METHODS OF DIAGNOSING ALZHEIMER'S DISEASE - Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease. | 07-07-2011 |
Helen Louise Byers, Cobham GB
| Patent application number | Description | Published |
|---|---|---|
| 20120071337 | METHODS - The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated. | 03-22-2012 |
Helen Louise Byers, London GB
| Patent application number | Description | Published |
|---|---|---|
| 20080213802 | Diagnosis of Neurodegenerative Diseases - The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed. | 09-04-2008 |
John S. Byers, Dundee GB
| Patent application number | Description | Published |
|---|---|---|
| 20090199164 | Interoperability method and software - Interoperability software modules comprise an architected .NET layer, an architected interpreter, an automatic interpreter and a library of COM objects. The architected interpreter where they are mapped to intermediate .NET interfaces compatible with the automatic interpreter by means of a Runtime Callable Wrapper (RCW). The architected interpreter also comprises an architected COM Callable Wrapper (CCW) that maps the intermediate COM interfaces into architected interfaces. | 08-06-2009 |